Staff

Heat Biologics Presents Positive Survival Benefit for HS-110 in Combination with Nivolumab in Phase 2 Lung Cancer Trial at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting

Median overall survival of 28.7 months in previously treated checkpoint inhibitor naïve non-small cell lung cancer patients Significantly greater median...

Modernizing Medicine Earns #1 Ranking for Integrated Practice Management, Revenue Cycle Management and EHR in Surgical Specialties by Black Book Research

Health IT company’s modmed BOOST and modmed gBOOST solutions recognized in inaugural report BOCA RATON, Fla.--(BUSINESS WIRE)--Specialty-specific healthcare information technology...

error: Content is protected !!